Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Non-Current Deffered Revenue (2018 - 2020)

KalVista Pharmaceuticals' Non-Current Deffered Revenue history spans 6 years, with the latest figure at $2.5 million for Q1 2020.

  • On a quarterly basis, Non-Current Deffered Revenue fell 31.81% to $2.5 million in Q1 2020 year-over-year; TTM through Jan 2020 was $2.5 million, a 31.81% decrease, with the full-year FY2019 number at $3.3 million, down 69.23% from a year prior.
  • Non-Current Deffered Revenue hit $2.5 million in Q1 2020 for KalVista Pharmaceuticals, down from $2.8 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for KALV hit a ceiling of $13.9 million in Q1 2018 and a floor of $49000.0 in Q1 2016.
  • Historically, Non-Current Deffered Revenue has averaged $5.3 million across 4 years, with a median of $3.5 million in 2019.
  • Biggest five-year swings in Non-Current Deffered Revenue: surged 2350.0% in 2016 and later tumbled 73.61% in 2019.
  • Tracing KALV's Non-Current Deffered Revenue over 4 years: stood at $49000.0 in 2016, then skyrocketed by 9430.61% to $4.7 million in 2018, then tumbled by 41.03% to $2.8 million in 2019, then fell by 9.22% to $2.5 million in 2020.
  • Business Quant data shows Non-Current Deffered Revenue for KALV at $2.5 million in Q1 2020, $2.8 million in Q4 2019, and $2.9 million in Q3 2019.